| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ryanodine Receptor Calcium Release Channel | 62 | 2021 | 134 | 8.240 |
Why?
|
| Calcium | 60 | 2023 | 354 | 5.670 |
Why?
|
| Calcium Signaling | 25 | 2023 | 110 | 3.540 |
Why?
|
| Sarcoplasmic Reticulum | 42 | 2021 | 157 | 3.270 |
Why?
|
| Ion Channel Gating | 27 | 2020 | 176 | 2.620 |
Why?
|
| Calcium Channels | 30 | 2013 | 106 | 2.510 |
Why?
|
| Myocytes, Cardiac | 15 | 2021 | 85 | 1.950 |
Why?
|
| Myocardium | 19 | 2016 | 100 | 1.870 |
Why?
|
| Animals | 80 | 2022 | 3295 | 1.650 |
Why?
|
| Calsequestrin | 7 | 2014 | 30 | 1.000 |
Why?
|
| Potassium | 7 | 2016 | 59 | 0.850 |
Why?
|
| Caffeine | 13 | 2014 | 53 | 0.810 |
Why?
|
| Magnesium | 7 | 2016 | 35 | 0.790 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2021 | 57 | 0.770 |
Why?
|
| Muscles | 13 | 2012 | 56 | 0.730 |
Why?
|
| Models, Cardiovascular | 2 | 2021 | 14 | 0.700 |
Why?
|
| Muscle Proteins | 9 | 1997 | 22 | 0.670 |
Why?
|
| Rats | 17 | 2013 | 626 | 0.640 |
Why?
|
| Computer Simulation | 2 | 2021 | 173 | 0.640 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 8 | 2003 | 22 | 0.620 |
Why?
|
| Models, Biological | 9 | 2018 | 303 | 0.620 |
Why?
|
| Heart Ventricles | 9 | 2013 | 82 | 0.590 |
Why?
|
| Tachycardia, Ventricular | 6 | 2021 | 20 | 0.590 |
Why?
|
| Membrane Potentials | 18 | 2016 | 166 | 0.570 |
Why?
|
| Heart | 9 | 2016 | 59 | 0.550 |
Why?
|
| Mutation | 11 | 2023 | 328 | 0.510 |
Why?
|
| Lipid Bilayers | 18 | 2016 | 48 | 0.480 |
Why?
|
| Peptides | 1 | 2016 | 89 | 0.470 |
Why?
|
| Rabbits | 16 | 2018 | 165 | 0.450 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 232 | 0.440 |
Why?
|
| Muscle Cells | 2 | 2013 | 12 | 0.430 |
Why?
|
| Ion Channels | 7 | 2013 | 204 | 0.430 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 3 | 2018 | 3 | 0.420 |
Why?
|
| Kinetics | 16 | 2018 | 176 | 0.410 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 10 | 2023 | 20 | 0.390 |
Why?
|
| Muscle Contraction | 8 | 2005 | 67 | 0.380 |
Why?
|
| Muscle, Skeletal | 7 | 2009 | 327 | 0.360 |
Why?
|
| Cytosol | 5 | 2018 | 40 | 0.350 |
Why?
|
| Mice | 17 | 2022 | 1250 | 0.350 |
Why?
|
| Microsomes | 11 | 2012 | 14 | 0.340 |
Why?
|
| Calcium Channel Agonists | 2 | 2009 | 2 | 0.340 |
Why?
|
| Patch-Clamp Techniques | 8 | 2014 | 97 | 0.330 |
Why?
|
| Diterpenes | 1 | 2010 | 4 | 0.330 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 3 | 2018 | 12 | 0.310 |
Why?
|
| Receptors, Cholinergic | 7 | 1993 | 24 | 0.310 |
Why?
|
| Trifluoperazine | 1 | 2009 | 2 | 0.300 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 34 | 0.300 |
Why?
|
| In Vitro Techniques | 13 | 2003 | 153 | 0.290 |
Why?
|
| Intracellular Space | 1 | 2008 | 5 | 0.290 |
Why?
|
| Calmodulin | 2 | 2019 | 7 | 0.280 |
Why?
|
| Mutant Proteins | 1 | 2008 | 6 | 0.280 |
Why?
|
| Cells, Cultured | 8 | 2018 | 468 | 0.280 |
Why?
|
| Mutation, Missense | 3 | 2017 | 24 | 0.280 |
Why?
|
| Myocardial Contraction | 5 | 2016 | 36 | 0.270 |
Why?
|
| Endoplasmic Reticulum | 3 | 2023 | 25 | 0.260 |
Why?
|
| HEK293 Cells | 8 | 2022 | 59 | 0.260 |
Why?
|
| Adaptation, Physiological | 4 | 2002 | 42 | 0.250 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 97 | 0.250 |
Why?
|
| Calcium Channel Blockers | 5 | 2011 | 30 | 0.250 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 7 | 2022 | 17 | 0.240 |
Why?
|
| Carbazoles | 3 | 2016 | 5 | 0.240 |
Why?
|
| Propanolamines | 3 | 2016 | 7 | 0.240 |
Why?
|
| Humans | 20 | 2022 | 22947 | 0.230 |
Why?
|
| Algorithms | 6 | 2016 | 304 | 0.230 |
Why?
|
| Dogs | 11 | 2004 | 136 | 0.230 |
Why?
|
| Protein Binding | 4 | 2019 | 114 | 0.210 |
Why?
|
| Protein Isoforms | 3 | 2009 | 36 | 0.210 |
Why?
|
| Chlorides | 3 | 2016 | 25 | 0.200 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2015 | 27 | 0.200 |
Why?
|
| Cytoplasm | 2 | 2003 | 33 | 0.200 |
Why?
|
| Permeability | 5 | 2008 | 94 | 0.200 |
Why?
|
| Intracellular Fluid | 1 | 2003 | 4 | 0.200 |
Why?
|
| Ligands | 7 | 2023 | 37 | 0.190 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 2 | 0.190 |
Why?
|
| Action Potentials | 7 | 2018 | 79 | 0.190 |
Why?
|
| Malignant Hyperthermia | 3 | 1993 | 15 | 0.190 |
Why?
|
| Cesium | 5 | 2009 | 13 | 0.190 |
Why?
|
| Infertility, Male | 1 | 2022 | 6 | 0.190 |
Why?
|
| CA1 Region, Hippocampal | 2 | 2020 | 8 | 0.180 |
Why?
|
| Heart Rate | 3 | 2016 | 104 | 0.180 |
Why?
|
| Ryanodine | 9 | 2002 | 17 | 0.180 |
Why?
|
| Pyramidal Cells | 2 | 2020 | 34 | 0.180 |
Why?
|
| Ethylenediamines | 3 | 1997 | 5 | 0.180 |
Why?
|
| Acetates | 3 | 1997 | 16 | 0.170 |
Why?
|
| Feedback, Physiological | 2 | 2012 | 12 | 0.170 |
Why?
|
| Photolysis | 5 | 2004 | 6 | 0.170 |
Why?
|
| Cations, Monovalent | 2 | 2012 | 11 | 0.160 |
Why?
|
| Alzheimer Disease | 2 | 2020 | 1320 | 0.160 |
Why?
|
| Calcium Channels, L-Type | 5 | 2019 | 50 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 108 | 0.160 |
Why?
|
| Amyloid beta-Peptides | 1 | 2020 | 198 | 0.150 |
Why?
|
| Cations, Divalent | 2 | 2012 | 10 | 0.150 |
Why?
|
| Intracellular Membranes | 6 | 2013 | 20 | 0.140 |
Why?
|
| Probability | 1 | 2018 | 71 | 0.140 |
Why?
|
| Cell Line | 6 | 2018 | 250 | 0.140 |
Why?
|
| Channelopathies | 1 | 2018 | 5 | 0.140 |
Why?
|
| Time Factors | 6 | 2020 | 1262 | 0.140 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2018 | 9 | 0.140 |
Why?
|
| Binge Drinking | 1 | 2018 | 8 | 0.140 |
Why?
|
| Neurons | 1 | 2020 | 273 | 0.140 |
Why?
|
| Chelating Agents | 2 | 1997 | 13 | 0.140 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 38 | 0.140 |
Why?
|
| Heart Atria | 1 | 2018 | 22 | 0.140 |
Why?
|
| Adenosine Triphosphate | 7 | 2013 | 21 | 0.140 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 173 | 0.130 |
Why?
|
| Ethanol | 1 | 2018 | 82 | 0.130 |
Why?
|
| Microscopy, Confocal | 3 | 2014 | 80 | 0.130 |
Why?
|
| Nebivolol | 1 | 2016 | 1 | 0.130 |
Why?
|
| Male | 12 | 2022 | 12458 | 0.120 |
Why?
|
| Scorpion Venoms | 1 | 2016 | 4 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 2003 | 147 | 0.120 |
Why?
|
| Molecular Sequence Data | 6 | 2003 | 185 | 0.120 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 5 | 2019 | 16 | 0.120 |
Why?
|
| Recombinant Proteins | 6 | 2003 | 164 | 0.120 |
Why?
|
| Electric Conductivity | 5 | 2008 | 68 | 0.110 |
Why?
|
| Cats | 3 | 2009 | 28 | 0.110 |
Why?
|
| Cardiomegaly | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mice, Mutant Strains | 4 | 2016 | 19 | 0.110 |
Why?
|
| COS Cells | 4 | 2003 | 38 | 0.110 |
Why?
|
| Rana pipiens | 4 | 2003 | 50 | 0.110 |
Why?
|
| Biological Transport | 1 | 2013 | 38 | 0.100 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 20 | 0.100 |
Why?
|
| Potassium Channels | 4 | 2020 | 36 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Cocaine | 1 | 2013 | 31 | 0.100 |
Why?
|
| Transfection | 5 | 2012 | 117 | 0.100 |
Why?
|
| Cell Membrane Permeability | 2 | 2012 | 50 | 0.100 |
Why?
|
| Swine | 4 | 2003 | 68 | 0.100 |
Why?
|
| Ethanolamines | 1 | 2012 | 2 | 0.090 |
Why?
|
| Fluorometry | 1 | 2012 | 5 | 0.090 |
Why?
|
| Lysine | 1 | 2012 | 14 | 0.090 |
Why?
|
| Cattle | 2 | 2011 | 111 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2010 | 54 | 0.090 |
Why?
|
| Thermodynamics | 1 | 2012 | 42 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2012 | 24 | 0.090 |
Why?
|
| Solutions | 2 | 2011 | 15 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 315 | 0.090 |
Why?
|
| Antibodies | 1 | 1991 | 43 | 0.080 |
Why?
|
| Binding Sites | 3 | 2019 | 68 | 0.080 |
Why?
|
| Sodium Compounds | 1 | 1990 | 4 | 0.080 |
Why?
|
| Perchlorates | 1 | 1990 | 5 | 0.080 |
Why?
|
| Dimerization | 2 | 2008 | 20 | 0.080 |
Why?
|
| Lithium | 1 | 2009 | 19 | 0.080 |
Why?
|
| Sodium | 1 | 2009 | 56 | 0.080 |
Why?
|
| Immunoblotting | 2 | 2014 | 54 | 0.080 |
Why?
|
| Amitriptyline | 1 | 2008 | 3 | 0.070 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2008 | 15 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 34 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 1999 | 18 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2018 | 109 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2005 | 39 | 0.070 |
Why?
|
| Barium | 2 | 1999 | 13 | 0.060 |
Why?
|
| Electrophysiology | 3 | 1999 | 95 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2012 | 39 | 0.060 |
Why?
|
| Arsenazo III | 1 | 1986 | 1 | 0.060 |
Why?
|
| Azo Compounds | 1 | 1986 | 3 | 0.060 |
Why?
|
| Proteolipids | 2 | 2003 | 6 | 0.060 |
Why?
|
| Diastole | 2 | 2018 | 28 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2005 | 17 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 69 | 0.060 |
Why?
|
| Signal Transduction | 2 | 1998 | 398 | 0.060 |
Why?
|
| Protein Conformation | 5 | 2013 | 65 | 0.060 |
Why?
|
| Ions | 3 | 2016 | 45 | 0.060 |
Why?
|
| Strontium | 1 | 2004 | 1 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 370 | 0.050 |
Why?
|
| Female | 7 | 2018 | 12954 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2004 | 113 | 0.050 |
Why?
|
| Electrocardiography | 2 | 2016 | 92 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2003 | 14 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 523 | 0.050 |
Why?
|
| Stochastic Processes | 2 | 2004 | 13 | 0.050 |
Why?
|
| Gene Knock-In Techniques | 2 | 2014 | 6 | 0.050 |
Why?
|
| Feedback | 1 | 2002 | 33 | 0.050 |
Why?
|
| Reference Values | 3 | 1993 | 169 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2018 | 131 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 1993 | 33 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 13 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2000 | 5 | 0.040 |
Why?
|
| Aging | 2 | 2018 | 1102 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 635 | 0.040 |
Why?
|
| Neuroprotection | 1 | 2020 | 2 | 0.040 |
Why?
|
| Dendritic Spines | 1 | 2020 | 8 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 17 | 0.040 |
Why?
|
| Long-Term Potentiation | 1 | 2020 | 13 | 0.040 |
Why?
|
| Reaction Time | 1 | 2000 | 78 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1999 | 33 | 0.040 |
Why?
|
| Cerebellum | 2 | 1998 | 34 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 2000 | 21 | 0.040 |
Why?
|
| Receptors, Nicotinic | 2 | 1990 | 5 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 144 | 0.040 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1999 | 4 | 0.040 |
Why?
|
| Plasmids | 1 | 1999 | 42 | 0.040 |
Why?
|
| Stimulation, Chemical | 2 | 1990 | 8 | 0.040 |
Why?
|
| Diffusion | 1 | 1999 | 24 | 0.040 |
Why?
|
| Biophysical Phenomena | 2 | 1998 | 26 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2013 | 315 | 0.040 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1998 | 1 | 0.040 |
Why?
|
| Biophysics | 2 | 1998 | 32 | 0.040 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 1998 | 2 | 0.040 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 4 | 0.040 |
Why?
|
| Electrochemistry | 2 | 1997 | 39 | 0.040 |
Why?
|
| DNA Primers | 2 | 2014 | 49 | 0.040 |
Why?
|
| Isolated Heart Preparation | 1 | 2018 | 2 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 1997 | 17 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2018 | 6 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 27 | 0.030 |
Why?
|
| Systole | 1 | 2018 | 13 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1998 | 88 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 31 | 0.030 |
Why?
|
| Apoptosis | 1 | 1999 | 196 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 85 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1997 | 125 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 97 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1997 | 10 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 8 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2013 | 79 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2007 | 87 | 0.030 |
Why?
|
| Diazonium Compounds | 1 | 1997 | 1 | 0.030 |
Why?
|
| Phenoxyacetates | 1 | 1997 | 1 | 0.030 |
Why?
|
| Phospholipids | 1 | 1997 | 9 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 6 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2016 | 8 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 1998 | 228 | 0.030 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2016 | 2 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 6923 | 0.030 |
Why?
|
| Putrescine | 1 | 1996 | 1 | 0.030 |
Why?
|
| Spermidine | 1 | 1996 | 1 | 0.030 |
Why?
|
| Spermine | 1 | 1996 | 1 | 0.030 |
Why?
|
| Endoplasmic Reticulum, Smooth | 1 | 1996 | 1 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 26 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 2016 | 42 | 0.030 |
Why?
|
| Aged | 2 | 2018 | 7447 | 0.030 |
Why?
|
| Fluorescent Dyes | 3 | 2003 | 34 | 0.030 |
Why?
|
| Middle Aged | 2 | 2018 | 7910 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2015 | 3 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 166 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1994 | 5 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2005 | 95 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 17 | 0.030 |
Why?
|
| Surface Properties | 1 | 1994 | 105 | 0.030 |
Why?
|
| Chloride Channels | 2 | 1991 | 7 | 0.030 |
Why?
|
| Point Mutation | 1 | 2014 | 25 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2013 | 2 | 0.030 |
Why?
|
| Dialysis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Echocardiography | 1 | 2014 | 68 | 0.030 |
Why?
|
| Calorimetry | 1 | 2013 | 4 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2013 | 22 | 0.030 |
Why?
|
| Papillary Muscles | 1 | 2013 | 1 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2014 | 282 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2013 | 32 | 0.030 |
Why?
|
| Light | 1 | 2013 | 55 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 1991 | 149 | 0.020 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2012 | 1 | 0.020 |
Why?
|
| Models, Chemical | 2 | 1997 | 42 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 6 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 29 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 103 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 442 | 0.020 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2003 | 13 | 0.020 |
Why?
|
| Bisoprolol | 1 | 2011 | 1 | 0.020 |
Why?
|
| Metoprolol | 1 | 2011 | 5 | 0.020 |
Why?
|
| Species Specificity | 1 | 1991 | 34 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 592 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1991 | 21 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 162 | 0.020 |
Why?
|
| Kidney | 1 | 2012 | 142 | 0.020 |
Why?
|
| Epitopes | 1 | 1991 | 39 | 0.020 |
Why?
|
| Histological Techniques | 1 | 1990 | 6 | 0.020 |
Why?
|
| Alkaloids | 1 | 1989 | 3 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 1989 | 7 | 0.020 |
Why?
|
| Nitrendipine | 1 | 1989 | 2 | 0.020 |
Why?
|
| Gallopamil | 1 | 1989 | 8 | 0.020 |
Why?
|
| Temperature | 1 | 1989 | 58 | 0.020 |
Why?
|
| Intercellular Junctions | 1 | 1988 | 8 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1988 | 59 | 0.020 |
Why?
|
| Ferrets | 2 | 1998 | 4 | 0.020 |
Why?
|
| bcl-X Protein | 2 | 1999 | 5 | 0.020 |
Why?
|
| Base Sequence | 2 | 1998 | 101 | 0.020 |
Why?
|
| Ion Exchange | 1 | 1988 | 1 | 0.020 |
Why?
|
| Membranes | 2 | 2002 | 9 | 0.020 |
Why?
|
| Absorption | 1 | 1986 | 3 | 0.020 |
Why?
|
| Rana temporaria | 1 | 1986 | 7 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1986 | 35 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1986 | 64 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2004 | 17 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 41 | 0.010 |
Why?
|
| Markov Chains | 1 | 2004 | 30 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 48 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 60 | 0.010 |
Why?
|
| Homeostasis | 1 | 2004 | 65 | 0.010 |
Why?
|
| Artifacts | 1 | 2003 | 29 | 0.010 |
Why?
|
| Biotransformation | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 35 | 0.010 |
Why?
|
| Tritium | 2 | 1993 | 8 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 112 | 0.010 |
Why?
|
| Sulfhydryl Reagents | 1 | 2000 | 1 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2000 | 3 | 0.010 |
Why?
|
| Dihydropyridines | 2 | 1991 | 5 | 0.010 |
Why?
|
| Anura | 1 | 2000 | 15 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2000 | 46 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2000 | 76 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 11 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 20 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1998 | 7 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1998 | 17 | 0.010 |
Why?
|
| Cell Survival | 1 | 1999 | 99 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1998 | 56 | 0.010 |
Why?
|
| Heparin | 1 | 1998 | 22 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1997 | 6 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1997 | 24 | 0.010 |
Why?
|
| Organic Chemicals | 1 | 1997 | 4 | 0.010 |
Why?
|
| Buffers | 1 | 1997 | 9 | 0.010 |
Why?
|
| Fluorescence | 1 | 1997 | 8 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 1997 | 22 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 112 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 78 | 0.010 |
Why?
|
| Cations | 1 | 1997 | 15 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1997 | 43 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1997 | 284 | 0.010 |
Why?
|
| Mammals | 1 | 1996 | 20 | 0.010 |
Why?
|
| Chickens | 1 | 1996 | 33 | 0.010 |
Why?
|
| Isomerism | 1 | 1993 | 1 | 0.010 |
Why?
|
| Calcium Radioisotopes | 1 | 1993 | 2 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1993 | 16 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1993 | 5 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1993 | 56 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1993 | 31 | 0.010 |
Why?
|
| Isradipine | 1 | 1989 | 2 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1989 | 2 | 0.000 |
Why?
|
| Alcohols | 1 | 1988 | 7 | 0.000 |
Why?
|
| Ruthenium Red | 1 | 1988 | 7 | 0.000 |
Why?
|
| Tromethamine | 1 | 1988 | 3 | 0.000 |
Why?
|